Birgitta Versluijs

149 Outcome predictors in Allo-LS in children Supplemental data TABLE S1. Univariate predictor analyses for Allo-LS free survival, BOS + IPS (N=53) Variable HR (95% CI), P value Age at Allo-LS 1.01 (0.96-1.07), p=0.69 Female 1.06 (0.52-2.14), p=0.88 Primary disease  Malignant  Bone marrow failure syndrome  Inborn error of metabolism  Primary Immune deficiency 1 0.87 (0.34-2.23), p=0.77 1.01 (0.21-4.90), p=0.99 1.09 (0.41-2.91), p=0.86 Stem cell source  Bone marrow  Cord blood  Peripheral blood stem cells 1 0.25 (0.3-2.00), p=0.19 0.32 (0.41-2.48), p=0.27 Unrelated donor 1.61 (0.66-3.94), p=0.29 Conditioning regimen  Myeloablative Busulfan based  Myeloablative total body irridiation (TBI) based  Reduced intensity conditioning (RIC), no/lower dose Busulfan  1 0.44 (0.13-1.47), p=0.18 0.55 (0.09-3.33), p=0.51 Human Leukocyte Antigen (HLA) mismatched* 1.98 (0.96-4.1), p=0.07 Hematopoietic cell transplantation (HCT) before 2008 0.75 (0.36-1.54), p=0.43 Respiratory viruses from broncho-alveolar lavage pre-HCT (n=36) 0.82 (0.32-2.08), p=0.67 Respiratory viruses from nasopharyngeal aspirate pre-HCT (n=48) 0.72 (0.33-1.56), p=0.40 Viral reactivation prior to Allo-LS 1.53 (0.75-3.10), p=0.24 Time from HCT to Allo-LS 0.99 (0.99-1.00), p=0.15 Time from symptoms to treatment Allo-LS 1.00 (0.99-1.02), p=0.71 Graft versus Host Disease treatment prior to Allo-LS 4.4 (1.76-11.12), p=0.002 Oxygen therapy 2.3 (0.8-6.59), p=0.12 Intensive care for mechanical ventilation 2.8 (1.38-5.74), p=0.005 Idiopathic Pneumonia Syndrome (IPS) Bronchiolitis Obliterans Syndrome (BOS) 1 0.57 (0.27-1.17), p=0.13 High resolution CT composite score (n=43) 1.03 (0.99-1.07), p=0.20 High resolution CT allo score (n=43) 1.03 (0.94-1.13), p=0.55 RV from NPA or BAL at diagnosis Allo-LS (n=43) 0.31 (0.14-0.72), p=0.006 * All 10/10 bone marrow/peripheral blood stem cell products and 6/6 cord blood units were considered matched. Allo-LS, Alloimmune mediated lung syndrome. 8